patients with primary hyperparathyroidism, undergoing parathyroidectomy, as a therapeutic intervention

patients with primary hyperparathyroidism, not undergoing parathyroidectomy and receiving conservative treatment. This group will be considered as control group.

patients undergoing thyroid surgery due to nontoxic multinodular goiter or solitary nontoxic thyroid adenoma. This group will be considered as control group.

healthy subjects. This group will be considered as control group.

Hyperparathyroidism, Primary

Parathyroidectomy

AHEPA University General Hospital, Aristotle University of Thessaloniki

Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.

Due to the fact that stapedius muscle is the smallest skeletal muscle in the human body, the investigators tend to measure stapedius reflex in order to test the hypothesis that there is association between acoustic reflex improvement and parathyroidectomy for PHPT.

Cardiovascular system will be evaluated by measuring Left Ventricular Mass Index (LVMI)

The investigators will assess muscle strength using isokinetic dynamometers

Concerning evaluation of cardiovascular system, the investigators will also appraise the levels of hs-CRP

Concerning evaluation of cardiovascular system, the investigators will also monitor patients' blood pressure for 24 hours.

The investigators will conduct neurological clinical examination and assess motor nerve conduction velocity, using electroneurography and neuromuscular junction, using electromyography

Pasiekas' questionnaire will be used to assess participant's quality of life.

International Physical Activity questionnaire will be used to assess participant's physical activity.

Papavramidis Theodossis

Assistant Professor of Surgery, Aristotle University of Thessaloniki

Aristotle University Of Thessaloniki

The intervention is K1-70 intramuscular or K1-70 intravenous. This is a single, ascending, intramuscular or intravenous dose, sequential group study.

Graves' Disease

Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.

K1-70 intramuscular or K1-70 intravenous

Royal Liverpool University Hospital Clinical Research Unit

Medicines Evaluation Unit

K1-70 - A Study in Subjects With Graves' Disease

K1-70 - A Phase I, Single Ascending Intramuscular Dose or Single Ascending Intravenous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease

Safety and tolerability testing consists of vital signs, ECG, blood samples for haematology, coagulation, clinical biochemistry and hormone panel, urine samples for urinalysis, eye examinations, physical examinations and examination of injection or infusion site. All clinically significant results and the number of treatment related adverse events will be reported.

The terminal elimination rate constant will be calculated and reported

The terminal elimination half life will be calculated and reported

Time of the maximum observed plasma concentration will be calculated and reported

Maximum observed plasma concentration will be calculated and reported

Area under the plasma concentration time curve to the last quantified concentration will be calculated and reported

Area under the plasma concentration time curve from time zero to infinity will be calculated and reported

Percentage of area under the plasma concentration time curve that is extrapolated will be calculated and reported

The level of antidrug antibodies present in the patient serum will be measured over time and reported.

TSH levels will be measured and reported over time.

Free T3 levels will be measured and reported over time.

Free T4 levels will be measured and reported over time.

TSH levels will be reported against baseline TRAb over time.

Free T3 levels will be reported against baseline TRAb over time.

Free T4 levels will be reported against baseline TRAb over time.

All clinically significant results and the number of treatment related adverse events will be reported.

AV7 Limited

Patients with hyperthyroidism admitted for treatment with radioiodine or antithyroid drugs

Hyperthyroidism

Atrial Fibrillation

Medicine Clinic, Sahlgrenska University Hospital

Endocrinology Clinik, Karolinska University Hospital

Medicine Clinic, Danderyds Hospital

Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE)

Upon inclusion, each patient will receive a thumb-ECG-monitor to take home. He/she will register his/her heart rhythm twice daily, and can also register at will upon symptoms. This will continue for 2 weeks, after which the monitor is returned.

When a patient comes back to the policlinic after hyperthyroidism treatment (typically 3 months later), the same procedure is performed as upon inclusion. Thumb-ECG-monitoring is performed during a 2-week period.

Risk factors for stroke in atrial fibrillation according to the CHADS-VASc-scoring system.

goiter/إعياء

Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.

K1-70 - A Study in Subjects With Graves' Disease

Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE)

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم